Is Kythera's Double Chin Drug A Winner?
One biotech company I am excited about is Kythera Biopharmaceuticals Inc. (KYTH). Kythera is developing ATX-101, an investigational injectable drug for the reduction of unwanted submental fat, commonly known as "double chin.
Kythera's potential first-in-class injectable drug candidate is a proprietary formulation of synthetic deoxycholic acid, an endogenous compound that is present in the body to promote the natural breakdown of dietary fat. ATX-101 is designed to be a locally-injected drug that causes proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue..
"Double chins" are caused by a layer of subcutaneous fat around the neck that sags down and creates a wrinkle, that has the resemblance of a second chin. Double chins are most commonly found on the elderly and the obese.
There are no drugs currently available to treat the fatty deposits that causes some double chins. People may opt
Complete Story »
Original Article: Is Kythera's Double Chin Drug A Winner?NEXT ARTICLE